CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN), a company focused on regenerative and aesthetics medicine using non-animal-derived recombinant human collagen technology, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference.

The conference will take place on September 8-9, 2025, at the Lotte New York Palace Hotel. Senior management will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.

News Market Reaction

+4.37%

2 alerts

+4.37% News Effect

-9.3% Trough Tracked

+$1M Valuation Impact

$34M Market Cap

0.1x Rel. Volume

On the day this news was published, CLGN gained 4.37%, reflecting a moderate positive market reaction. Argus tracked a trough of -9.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $34M at that time.

Data tracked by StockTitan Argus on the day of publication.

REHOVOT, Israel, Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference on Monday, September 8^th and Tuesday September 9^th, 2025, at the Lotte New York Palace Hotel.

Investors attending the event may request a one-on-one meeting with CollPlant through their H.C. Wainwright representative or e-mail meetings@hcwco.com.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com.

Contacts

CollPlant:
Eran Rotem
Deputy CEO & CFO
+972-73-2325600
Eran@collplant.com

Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/collplant-to-participate-in-the-upcoming-27th-annual-hc-wainwright-global-investment-conference-302537524.html

SOURCE CollPlant

FAQ

When is CollPlant (NASDAQ:CLGN) presenting at the H.C. Wainwright Conference 2025?

CollPlant will participate in the conference on September 8-9, 2025 at the Lotte New York Palace Hotel.

How can investors meet with CollPlant management at the H.C. Wainwright Conference?

Investors can request one-on-one meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.

What is CollPlant Biotechnologies' main technology focus?

CollPlant specializes in regenerative and aesthetics medicine using their proprietary non-animal-derived recombinant human collagen (rhCollagen) technology.

Where will the H.C. Wainwright Global Investment Conference 2025 be held?

The conference will be held at the Lotte New York Palace Hotel in New York.